Catalog No.: PC-22284Not For Human Use, Lab Use Only.
CDD-2693 (CDD2693) is a potent, selective pan-ephrin receptor kinase (EPH receptor) inhibitor with binding Ki of 4.0/0.81 nM for EPHA2/EPHA4, respectively.
CDD-2693 (CDD2693) is a potent, selective pan-ephrin receptor kinase (EPH receptor) inhibitor with binding Ki of 4.0/0.81 nM for EPHA2/EPHA4, respectively.
CDD-2693 shows nanomolar activity versus EPHA2 (IC50: 461 nM) and EPHA4 (IC50: 40 nM) but is a micromolar inhibitor of SRC, YES, and FGR.
CDD-2693 significantly decreases EFNA5 (ligand) induced phosphorylation of EPHA2/4, decreases 12Z cell viability, and decreases IL-1β-mediated expression of prostaglandin synthase 2 (PTGS2) in 12Z endometriotic epithelial cells.
CDD-2693 decreases expansion of primary endometrial epithelial organoids from patients with endometriosis and decreases Ewing's sarcoma viability.
